| 161.38 -2.56 (-1.56%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 194.4 | 1-year : | 227.06 |
| Resists | First : | 166.44 | Second : | 194.4 |
| Pivot price | 152.73  |
|||
| Supports | First : | 146.39 | Second : | 134 |
| MAs | MA(5) : | 162.77 |
MA(20) : | 150.83 |
| MA(100) : | 116.81 |
MA(250) : | 90.61 |
|
| MACD | MACD : | 7 |
Signal : | 6.2 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 93.4 |
| RSI | RSI(14): 68.7 |
|||
| 52-week | High : | 166.44 | Low : | 60.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INSM ] has closed below upper band by 28.8%. Bollinger Bands are 88.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 164.68 - 165.49 | 165.49 - 166.15 |
| Low: | 159.08 - 160.19 | 160.19 - 161.09 |
| Close: | 159.84 - 161.51 | 161.51 - 162.85 |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Tue, 14 Oct 2025
UBS Raises Price Target for Insmed (INSM) Following Consistent " - GuruFocus
Tue, 14 Oct 2025
UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating - MarketScreener
Tue, 14 Oct 2025
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today - Sahm
Mon, 13 Oct 2025
Insmed Incorporated (INSM) Stock Analysis: Biotechnology Growth with a 3.28% Potential Upside - DirectorsTalk Interviews
Thu, 09 Oct 2025
Insmed stock hits 52-week high at 164.04 USD - Investing.com
Fri, 03 Oct 2025
A Fresh Look at Insmed (INSM) Valuation Following Its Recent Momentum - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 211 (M) |
| Shares Float | 190 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 10,730 (K) |
| Shares Short P.Month | 10,560 (K) |
| EPS | -5.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.92 |
| Profit Margin | -259.9 % |
| Operating Margin | -236.4 % |
| Return on Assets (ttm) | -27.1 % |
| Return on Equity (ttm) | -160.6 % |
| Qtrly Rev. Growth | 18.8 % |
| Gross Profit (p.s.) | 1.42 |
| Sales Per Share | 1.88 |
| EBITDA (p.s.) | -4.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -845 (M) |
| Levered Free Cash Flow | -542 (M) |
| PE Ratio | -28.42 |
| PEG Ratio | 0 |
| Price to Book value | 27.26 |
| Price to Sales | 85.68 |
| Price to Cash Flow | -40.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|